通过基于结构的虚拟查发现的小分子TLR4激动剂的辅助活性
Mohammad Kadivella1,2, Vivek P Varma1, Jusail Cp1,2
1Laboratory of Vaccine Immunology, National Institute of Animal Biotechnology, Hyderabad, India.
Communications biology
|September 30, 2025
概括
确定了新的合成小分子托尔类受体4 (TLR4) 激动剂NSF-951,NSF-418和NSF-501. NSF-951作为一种强大的TLR4激动剂,增强疫苗反应,而NSF-418和NSF-501是对抗剂.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 药用化学 医学化学
背景情况:
- 单酸脂A (MPLA) 是一种经过临床批准的托尔类受体4 (TLR4) 激动剂,作为疫苗辅助剂使用.
- 复杂的结构和潜在的毒性限制了MPLA的广泛应用.
- 合成的小分子TLR4激动剂在合成,成本和安全方面具有优势.
研究的目的:
- 通过基于结构的虚拟查来识别新的小分子TLR4激动剂和对抗剂.
- 评估已识别的化合物的体外和体内疗效和安全性.
- 在疫苗接种模型中评估新型TLR4激动剂的辅助潜力.
主要方法:
- 基于结构的ZINC数据库对人类,小鼠和牛TLR4.4进行虚拟选.
- 在体外测试测量细胞因子生产 (IL-6,TNF-α) 和免疫细胞标志物表达 (CD80,CD86).
- 使用卵泡胺 (OVA) 抗原进行体内小鼠免疫研究,评估抗体和T细胞反应与或没有辅助剂.
主要成果:
- 确定了三种化合物,NSF-418,NSF-501和NSF-951.这些化合物中含有.
- NSF-951表现出强大的TLR4激动活性,诱导促炎性细胞因子并增强免疫细胞成熟.
- NSF-418和NSF-501表现出对抗性质,抑制MPLA诱导的反应.
- 在小鼠中,NSF-951显著增强了OVA特异性抗体和T细胞反应,没有观察到毒性.
结论:
- NSF-951是一种有前途,具有成本效益的TLR4激动剂,具有显著的免疫刺激和辅助潜力.
- NSF-418和NSF-501的功能是TLR4的对手.
- NSF-951需要进一步研究以开发为人类和兽医应用的下一代疫苗辅助剂.
更多相关视频
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
917
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
917
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K


